• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
JIA Chengshu, WANG Junwei, LI Hui, ZHU Qihua, GE Yiran, XU Yungen. Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2017, 48(5): 523-528. DOI: 10.11665/j.issn.1000-5048.20170503
Citation: JIA Chengshu, WANG Junwei, LI Hui, ZHU Qihua, GE Yiran, XU Yungen. Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance[J]. Journal of China Pharmaceutical University, 2017, 48(5): 523-528. DOI: 10.11665/j.issn.1000-5048.20170503
shu

Advances of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome drug resistance

More Information
    Graphical Abstract
    • Abstract
  • Phosphoinositide 3-kindase, an important signal transduction molecule in cells, plays a key role in the process of cell survival, proliferation and differentiation. Significant progress has been made in the treatment of cancer with PI3K inhibitors, yet the drug resistance of PI3K inhibitors affects their long-term efficacy in clinical treatment. In order to overcome the drug resistance, a variety of rational combined therapies have been developed. In this paper, the research progress of phosphoinositide-3 kinase inhibitors in combination with other drugs to overcome the drug resistance were reviewed.
    • FullText(HTML)
    • References (42)
  • [1]
    Lorusso PM.Inhibition of the PI3K/AKT/mTOR pathway in solid tumors[J].J Clin Oncol,2016,34(31):3803-3815.
    [2]
    Perrotta M, Lembo G, Carnevale D. The multifaceted roles of PI3Kγ in hypertension,vascular biology,and inflammation[J].Int J Mol Sci,2016,17(11):1858-1867.
    [3]
    Okkenhaug K,Graupera M,Vanhaesebroeck B.Targeting PI3K in cancer:impact on tumor cells,their protective stroma,angiogenesis,and immunotherapy[J].Cancer Discov,2016,6(10):1090-1105.
    [4]
    Marone R,Cmiljanovic V,Giese B,et al.Targeting phosphoinositide 3-kinase:moving towards therapy[J].Biochim Biophys Acta,2008,1784(1):159-185.
    [5]
    Vlahos CJ,Matter WF,Hui KY,et al.A specific inhibitor of phosphatidylinositol 3-kinase,2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one(LY294002)[J].J Biol Chem,1994,269(7):5241-5248.
    [6]
    Ihle NT,Williams R,Chow S,et al.Molecular pharmacology and antitumor activity of PX-866,a novel inhibitor of phosphoinositide-3-kinase signaling[J].Mol Cancer Ther,2004,3(7):763-772.
    [7]
    Folkes AJ,Ahmadi K,Alderton WK,et al.The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d] pyrimidine(GDC-0941)as a potent,selective,orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer[J].J Med Chem,2008,51(18):5522-5532.
    [8]
    Maira SM,Stauffer FJ,Furet P,et al.Identification and characterization of NVP-BEZ235,a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity[J].Mol Cancer Ther,2008,7(7):1851-1863.
    [9]
    Sutherlin DP,Bao L,Berry M,et al.Discovery of a potent,selective,and orally available class I phosphatidylinositol 3-kinase(PI3K)/mammalian target of rapamycin(mTOR)kinase inhibitor(GDC-0980)for the treatment of cancer[J].J Med Chem,2011,54(21):7579-7587.
    [10]
    Yu P,Laird AD,Du X,et al.Characterization of the activity of the PI3K/mTOR inhibitor XL765(SAR245409)in tumor models with diverse genetic alterations affecting the PI3K pathway[J].Mol Cancer Ther,2014,13(5):1078-1091.
    [11]
    Blajecka K,Borgström A,Arcaro A.Phosphatidylinositol 3-kinase isoforms as novel drug targets.[J].Curr Drug Targets,2011,12(7):1056-1081.
    [12]
    Hewett YG, Uprety D, Shah BK. Idelalisib- a PI3Kδ targeting agent for B-cell malignancies[J].J Oncol Pharm Pract,2016,22(2):284-288.
    [13]
    Sabbah DA,Hu J,Zhong HA.Advances in the development of class I phosphoinositide 3-kinase(PI3K)inhibitors[J].Curr Top Med Chem,2015,16(13):1413-1426.
    [14]
    Rodon J, Dienstmann R, Serra V, et al. Development of PI3K inhibitors:lessons learned from early clinical trials[J].Nat Rev Clin Oncol,2013,10(3):143-153.
    [15]
    Fruman DA,Rommel C.PI3K and cancer:lessons,challenges and opportunities[J].Nat Rev Drug Discov,2014,13(2):140-156.
    [16]
    Cao PR,Kong YL,Luo YM,et al.Mechanisms of resistance to PI3K-Akt-mTOR signaling pathway inhibitors[J].Chin Pharm J,2016,51(4):253-258.
    [17]
    Liu P,Cheng H,Roberts TM,et al.Targeting the phosphoinositide 3-kinase pathway in cancer[J].Nat Rev Drug Discov,2009,8(8):627-644.
    [18]
    Serra V,Scaltriti M,Prudkin L,et al.PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer[J].Oncogene,2011,30(22):2547-2557.
    [19]
    Floris G,Wozniak A,Sciot R,et al.A potent combination of the novel PI3K inhibitor,GDC-0941,with imatinib in gastrointestinal stromal tumor xenografts:long-lasting responses after treatment withdrawal[J].Clin Cancer Res,2013,19(3):620-630.
    [20]
    Pérez-Tenorio G,Alkhori L,Olsson B,et al.PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer[J].Clin Cancer Res,2007,13(12):3577-3584.
    [21]
    Krop IE,Saura C,Ahnert JR,et al.A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer[C].Meeting of the American-Society-of-Clinical-Oncology,2012.
    [22]
    Shimizu T,Tolcher AW,Papadopoulos KP,et al.The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer[J].Clin Cancer Res,2012,18(8):2316-2325.
    [23]
    Wu YL,Maachani UB,Schweitzer M,et al.Dual inhibition of PI3K/AKT and MEK/ERK pathways induces synergistic antitumor effects in diffuse intrinsic pontine glioma cells[J].Transl Oncol,2017,10(2):221-228.
    [24]
    Engelman JA,Chen L,Tan XH,et al.Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers[J].Nature Med,2008,14(12):1351-1356.
    [25]
    Wei BR,Michael HT,Halsey CH,et al.Synergistic targeted inhibition of MEK and dual PI3K/mTOR diminishes viability and inhibits tumor growth of canine melanoma underscoring its utility as a preclinical model for human mucosal melanoma[J].Pigment Cell Melanoma Res,2016,29(6):643-655.
    [26]
    Bedard PL,Tabernero J,Janku F,et al.A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib(BKM120)in combination with the oral MEK1/2 inhibitor trametinib(GSK1120212)in patients with selected advanced solid tumors[J].Clin Cancer Res,2015,21(4):730-738.
    [27]
    Ilic N,Utermark T,Widlund HR,et al.PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E(eIF4E)axis[J].Proc Natl Acad Sci U S A,2011,108(37):699-708.
    [28]
    Dawson MA,Prinjha RK,Dittmann A,et al.Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia[J].Nature,2011,478(7370):529-533.
    [29]
    Mertz JA,Conery AR,Bryant BM,et al.Targeting MYC dependence in cancer by inhibiting BET bromodomains[J].Proc Natl Acad Sci U S A,2011,108(40):16669-16674.
    [30]
    Stratikopoulos EE,Dendy M,Szabolcs M,et al.Kinase and BET inhibitors together clamp inhibition of PI3K signaling and overcome resistance to therapy[J].Cancer Cell,2015,27(6):837-851.
    [31]
    Granato M,Rizzello C,Romeo M A,et al.Concomitant reduction of c-Myc expression and PI3K/AKT/mTOR signaling by quercetin induces a strong cytotoxic effect against Burkitt′s lymphoma[J].Int J Biochem Cell B,2016,79:393-400.
    [32]
    Kumar A,Fernandez-Capetillo O,Carrera AC.Nuclear phosphoinositide 3-kinase beta controls double-strand break DNA repair[J].Proc Natl Acad Sci U S A,2010,107(16):7491-7496.
    [33]
    Ibrahim YH, Garcíagarcía C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition[J].Cancer Discov,2012,2(11):1036-1047.
    [34]
    Wang D,Li C,Zhang Y,et al.Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes[J].Gynecol Oncol,2016,142(3):548-556.
    [35]
    Juvekar A,Burga LN,Hu H,et al.Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer[J].Cancer Discov,2012,2(11):1048-1063.
    [36]
    Baselga J,Campone M,Piccart M,et al.Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer[J].N Engl J Med,2012,366(6):520-529.
    [37]
    Miller TW,Balko JM,Arteaga CL.Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer[J].J Clin Oncol,2011,29(33):4452-4461.
    [38]
    Mayer IA,Fasching PA,Gnant M,et al.Phase II,randomized,placebo-controlled study of BYL719 or buparlisib(BKM120)with letrozole for neoadjuvant treatment of postmenopausal women with HR+/HER2-,PIK3CA mutant or wild-type,breast cancer(BC)[J].J Clin Oncol,2014,32:5s.
    [39]
    Santarpia L,Lippman SM,Elnaggar AK.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy[J].Expert Opin Ther Targets,2012,16(1):103-119.
    [40]
    Coffee EM,Faber AC,Roper J,et al.Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E)colorectal cancer[J].Clin Cancer Res,2013,19(10):2688-2698.
    [41]
    Davids MS,Deng J,Wiestner A,et al.Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia[J].Blood,2012,120(17):3501-3509.
    [42]
    Rahmani M,Aust MM,Attkisson E,et al.Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism[J].Cancer Res,2012,73(4):1340-1351.
    • Related Articles

  • Related Articles

    [1]YANG Qian, WANG Xiaojian. Research progress of sphingosine kinase 1 inhibitors[J]. Journal of China Pharmaceutical University, 2021, 52(6): 759-768. DOI: 10.11665/j.issn.1000-5048.20210615
    [2]LI Yin, GU Hongfeng, ZOU Yi, WANG Shuping, XU Yungen. Research progress of mono-(ADP-ribosyl) transferase family and their inhibitors in tumor therapy[J]. Journal of China Pharmaceutical University, 2021, 52(6): 643-652. DOI: 10.11665/j.issn.1000-5048.20210601
    [3]BU Hong, ZHOU Jinpei, ZHANG Huibin. Research progress of mitogen-activated protein kinase interacting kinases inhibitors in tumor immunotherapy[J]. Journal of China Pharmaceutical University, 2021, 52(4): 410-421. DOI: 10.11665/j.issn.1000-5048.20210403
    [4]FENG Yang, XU Xiao, MO Ran. Advances in lymphatic targeted drug delivery system for treatment of tumor metastasis[J]. Journal of China Pharmaceutical University, 2020, 51(4): 425-432. DOI: 10.11665/j.issn.1000-5048.20200406
    [5]TIAN Jiping, ZHANG Jian, ZHOU Jinpei, ZHANG Huibin. Advances in small molecule inhibitors of PD-1/PD-L1 immune checkpoint pathway[J]. Journal of China Pharmaceutical University, 2019, 50(1): 1-10. DOI: 10.11665/j.issn.1000-5048.20190101
    [6]LIU Kejun, ZHANG Zhimin, RAN Ting, CHEN Hongli, LU Tao, CHEN Yadong. Advances in BET bromodomain protein inhibitors[J]. Journal of China Pharmaceutical University, 2015, 46(3): 264-271. DOI: 10.11665/j.issn.1000-5048.20150302
    [7]ZHANG Yuan, CHENG Yulan, ZHOU Jinpei, ZHANG Huibin. Advances on receptor tyrosine kinase inhibitors taking c-Met as anti-tumor target[J]. Journal of China Pharmaceutical University, 2015, 46(1): 16-27. DOI: 10.11665/j.issn.1000-5048.20150102
    [8]LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
    [9]DENG Lian-bai, LI Ai-xiu, JIN Yu-rui. Advances in the study on inhibitors of RNase H,a novel anti-HIV drug target[J]. Journal of China Pharmaceutical University, 2011, 42(6): 578-584.
    [10]KONG Kai-lai, LU Shuai, GAO Yi-ping, YANG Pei, TANG Wei-fang, LU Tao. Advances on the study of PLK1 inhibitors as antitumor agents[J]. Journal of China Pharmaceutical University, 2011, 42(1): 9-15.

  • Cited by

    Periodical cited type(2)

    1. 郁莉，蒋颖敏，许磊，朱景宇. 分子对接与分子动力学模拟法探究PI3Kδ/度维利塞(Duvelisib)的选择性结合. 化学研究与应用. 2022(02): 341-348 .
    2. 蔡燕飞，陈蕴，史劲松，金坚. 抗肿瘤药物体外药效学评价结合细胞生物学实验教学促进教研融合. 实验室研究与探索. 2020(08): 192-195 .

    Other cited types(0)

Catalog

    Get Citation
    PDF
    XML
    Article views (1196) PDF downloads (2107) Cited by(2)
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：285535

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return